Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Discrete Choice Experiment to Understand Patient Preferences for Self-Injectable Preventive Treatments for Migraine – A quantitative pilot
Headache
Headache Posters (7:00 AM-5:00 PM)
116
To quantify the trade-offs people with migraine are willing to make between attributes of preventive treatments.
Self-injectable calcitonin gene-related peptide monoclonal antibodies for migraine prevention appear to have comparable safety and efficacy, such that administration aspects may be important for treatment selection.
Adults from the US, the UK, and Germany with self-reported episodic or chronic migraine of at least moderate severity and experience with prescription preventive treatments participated in an online pilot discrete choice experiment (DCE). The DCE elicited preferences for seven device attributes identified from a targeted literature review and in-person focus groups: ‘dosing schedule’, ‘storage requirements’, ‘base and pinching’, ‘injection steps’, ‘injection duration’, ‘needle removal’, and ‘dose confirmation’. Participants chose between two administration devices described by these attributes and an oral alternative. Logit models were used to obtain relative attribute importance (RAI) and to predict the probability of patients’ preferences for autoinjector profiles.
304 participants (episodic migraine, 52.6%; female, 53.9%; mean age 42.0 years) completed the pilot DCE. Participants valued longer storage at room temperature (RAI: 37.2%), a shorter injection duration (RAI: 24.3%), needle auto-retraction (RAI: 19.6%), a wide autoinjector base (RAI: 8.1%), twisting to unlock (RAI: 5.4%), once-monthly injections (RAI: 2.7%) and dose confirmation via a 360-degree window (RAI: 2.7%). Based on elicited preferences for the considered attributes, a higher proportion of patients (47.2%) preferred an attribute profile comparable to galcanezumab over profiles comparable to erenumab (24.9%), fremanezumab once a month (14.3%), and fremanezumab every 3 months (13.6%).
Key drivers for device preferences were storage requirements, a short injection duration, needle auto-retraction, and a wide autoinjector base. Patients preferred a profile similar to galcanezumab over profiles of other self-injectable migraine preventive treatments. The preference information may enhance communication about potentially effective migraine preventive treatment options.
Authors/Disclosures
Jaein Seo (Evidera)
PRESENTER 		Jaein Seo has received personal compensation for serving as an employee of Evidera.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Robert A. Nicholson, PhD (Eli Lilly & Company) Dr. Nicholson has received personal compensation for serving as an employee of Eli Lilly & Company. Dr. Nicholson has stock in Eli Lilly & Company. Dr. Nicholson has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
Antje Tockhorn-Heidenreich Antje Tockhorn-Heidenreich has received personal compensation for serving as an employee of Eli Lilly and Company. An immediate family member of Antje Tockhorn-Heidenreich has received personal compensation for serving as an employee of Evidera. Antje Tockhorn-Heidenreich has received stock or an ownership interest from Eli Lilly and Company . An immediate family member of Antje Tockhorn-Heidenreich has received stock or an ownership interest from PPD.